Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine · 1 trial · 2 indications
CIN2+ was defined as CIN grade 2 (CIN2), CIN grade 3 (CIN3), adenocarcinoma in situ (AIS) or invasive cervical cancer. Preceding cervical cytology means the last cervical cytology specimen collected before the histopathology specimen was obtained. Subjects were human papillomavirus (HPV) deoxyribonucleic acid (DNA) negative (DNA-) by polymerase chain reaction (PCR) at Month 0 and Month 6 for the corresponding HPV-type.
| Arm | Type | Description |
|---|---|---|
| Cervarix Group | EXPERIMENTAL | Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm. |
| Havrix Group | ACTIVE_COMPARATOR | Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm. |
| Name | Type | Description |
|---|---|---|
| human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine | BIOLOGICAL | Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule |
| hepatitis A inactivated virus vaccine | BIOLOGICAL | Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule |
DISEASE CHARACTERISTICS: •Healthy participants * Deemed to be in good general health by history and physical examination •Resident of Guanacaste Province of Costa Rica and surrounding areas * Must remain a resident for ≥ 6 months after the first study vaccination PATIENT CHARACTERISTICS: Age ...
Top 20 of 26 competitors